diff --git a/journals/2024_10_31.md b/journals/2024_10_31.md
index afb1ce10..1f10ebaa 100644
--- a/journals/2024_10_31.md
+++ b/journals/2024_10_31.md
@@ -19,7 +19,8 @@
 			- Stella agrees. Its more showing the path that it takes for new products to be able to be sent out to the masses than the process where is now.
 			- Demonstrating that doing the pivotal trial and submit to regulatory agencies doesn't mean inclusion in programs.
 			- I got in touch with EDCTP authorities to highlight that PZQ and moxi and fdc are all edctp invesments. They are very happy about it.
-			- Maurice: what i gather is present the clinical findings and highlight what the next steps are. Im'
+			- Maurice: what i gather is present the clinical findings and highlight what the next steps are. Im not in the access program. I just know generalically. They're trying to get aproval in Kenya. I cannot give many specifics but yes about the pivotal trials. The panel can take it from there.
+			- Stella: Those iinvolved in the access will be in the audience. Look at the path from inception to
 		- ### Decisiones
 			-
 	- CANCELED 17:00 - 17:30: Pre-Symposium meeting